초록 ▼

The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The

The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrate to form the tissues and organs.

대표청구항 ▼

We claim: 1. Electrodeposited fibrin matrix with cells, wherein the cells are delivered to the matrix during fabrication of the electrodeposited fibrin matrix, wherein the cells are suspended in a solution comprising molecules capable of forming fibrin during delivery to the matrix, and wherein the

We claim: 1. Electrodeposited fibrin matrix with cells, wherein the cells are delivered to the matrix during fabrication of the electrodeposited fibrin matrix, wherein the cells are suspended in a solution comprising molecules capable of forming fibrin during delivery to the matrix, and wherein the cells are oriented through application of stretching mechanical force to the electrodeposited fibrin matrix. 2. The electrodeposited fibrin matrix with cells of claim 1, further comprising one or more substances. 3. The electrodeposited fibrin matrix with cells of claim 2, wherein the one or more substances is a growth factor, differentiation inducer, anti-oxidant, vitamin, hormone, nucleic acid, drug, peptide, emollient, humectant, conditioner or cosmetic. 4. A method of evaluating a biological response of a cell to a substance, comprising: applying the substance to the electrodeposited fibrin matrix with cells of claim 1; and, evaluating the biological response of the cell. 5. The method of claim 4, wherein the cell is a cancer cell. 6. An electrodeposited fibrin matrix with cells, wherein the cells are entrapped within the matrix during fabrication of the electrodeposited fibrin matrix, wherein the cells are suspended in a fibrinogen solution during delivery to the matrix, and wherein the cells are oriented through application of stretching mechanical force to the electrodeposited fibrin matrix. 7. The electrodeposited fibrin matrix with cells of claim 1, wherein the cells are spread in parallel with the applied stretching mechanical force. 8. The electrodeposited fibrin matrix of any one of claims 1, 6 or 7, further comprising a cross-linking agent. 9. The electrodeposited fibrin matrix of any one of claims 1, 6, or 7, further comprising calcium.